HR 6227
118th Congress
House
Health
Cardiovascular and respiratory health
Drug safety, medical device, and laboratory regulation
Health promotion and preventive care
Prescription drugs
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
Introduced: November 3, 2023
Introduced by:
Schweikert, David
Republican
· Arizona
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 10, 2023
Referred to the Subcommittee on Health.
Nov 3, 2023
Referred to the House Committee on Energy and Commerce.
Nov 3, 2023
Introduced in House
Plain-English summary
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
2